Bone morphogenetic protein in spinal fusion: overview and clinical update.
The widespread use of fusion procedures in the management of spinal disorders has led investigators to explore the use of growth and differentiation factors in such procedures. As an adjuvant to allograft bone or as a replacement for harvested autograft, bone morphogenetic proteins (BMPs) appear to improve fusion rates after spinal arthrodesis in both animal models and humans, while reducing the donor-site morbidity previously associated with such procedures. The use of recombinant genetic technology in the production of BMP has improved the efficiency, cost effectiveness, and safety of producing and using such materials. Recombinant human BMP-2 (rhBMP-2), as one of the first factors identified in the process of endochondral bone formation, has been extensively researched over the past decade. The efficacy and dose profile of this differentiation factor in the context of various carrier substrates has been investigated. Based on the encouraging results of preliminary studies, the future role of rhBMP-2 may lie in its replacement of autologous bone grafting and, consequently, the reduced need for instrumented fixation, while concurrently improving overall fusion rates. The authors provide an overview of BMP and review its use in clinical and laboratory settings.
Subach
B R
BR
Department of Neurological Surgery, Emory University, Atlanta, Georgia, USA.
Haid
R W
RW
Rodts
G E
GE
Kaiser
M G
MG
D000818:Animals; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D006801:Humans; D010012:Osteogenesis / Q000235:genetics*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013123:Spinal Fusion
D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins